agencies around the world in doing something about improving the life of patients and caregivers. He projected this vision clearly and engagingly, in seminars, advisory boards, and personal discussions in the bar or at a dinner table. He made us achieve the impossible by a simple 'Don't worry, it'll be OK' . On the other hand, in committee meetings he could be brutally candid about pitfalls, and he could graciously annihilate scientific posturizing at conferences. In his inimitable David Cox way, walking up to the microphone and friendly summarizing in under ten words the stretch of the claim. His funny outspokenness was very refreshing. To a packed room at a public session of an ASHG meeting in his beloved home town San Francisco, he once discussed the genetic gender testing in sports, and the personal grief the new genetics sometimes brought. 'Finally' , he ended, 'they went back to doing it how it worked so well before-by just looking at them' .
David was a true world-citizen, at home in Europe, Asia, and the Americas. Travelling and lecturing, sitting on HUGO Council or other committees, he has crucially contributed to shaping the human genome project and today's large-scale genetics and biobanking. Aiming at advancing science as well as the social fabric, he was passionate about the value and vulnerability of the worlds' cultural differences, as well as about the need for public-private partnerships. In an interview in 2010, he said, 'Call me a dreamer, but I think if you look at the people who participate in trials, or contribute to population or clinical biobanks, what they ultimately want, the reason they participate, is an altruistic one: they want to help improve society by providing the materials and data that will help scientists and companies to improve the quality of peoples' lives' (http://bbmri.nl/ images/stories/hub2_web.pdf).
We will sorely miss him. Starting as a paediatrician/genetic counsellor, he became a counsellor of geneticists. We gratefully acknowledge his teachings. The best way to fulfil the debt we owe him for his lifelong efforts is to continue what he has set in motion: academia, industry, the patient community, and the public at large joining forces to improve biological insights to make better treatments.
